Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis

Table 1 Details of clinico-pathologic data and expression of Mcm2 in diffuse large B-cell lymphomas

Variable	Categorisation	n analysable	%
*Clinico-pathologic data:*
Age at diagnosis
	median 67 years (interquartile range 54–75 years)
	<65 years	69	43.1
	≥65 years	91	56.9
Gender
	male	97	53.3
	female	85	46.7
Ann Arbor stage
	1	27	17.3
	2	50	32.1
	3	34	21.8
	4	45	28.8
International prognostic index (IPI)
	0	2	1.3
	1	66	43.4
	2	29	19.1
	3	32	21.1
	4	23	15.1
Bone marrow involvement
	yes	44	28.6
	no	110	71.4
Extranodal involvement
	yes	54	35.8
	no	97	64.2
Bulky disease
	yes	94	64.4
	no	52	35.6
Chemotherapy
	no therapy	7	4.6
	CHOP	69	45.1
	other	77	50.3
Serum levels of LDH at diagnosis
	median 306 U/l (interquartile range 185–443 U/l)
	<300 U/l	61	49.2
	≥300 U/l	63	50.8
*Immunohistochemistry:*
Mcm2 immunoreactivity
	median 38% (interquartile range 29%–48%)
	<40%	113	53.6
	≥40%	98	46.4

ISSN: 1471-2407